Company Filing History:
3 out of 4,447 
3 out of 1,274 
Years Active: 2020-2024
Title: Andrew Philip Leaver-Fay: Innovator in Bi-Specific Antibodies
Introduction
Andrew Philip Leaver-Fay is a notable inventor based in Carrboro, NC (US). He has made significant contributions to the field of bi-specific antibodies, holding a total of 3 patents. His work focuses on innovative methods for producing these antibodies, which have important applications in therapeutic development.
Latest Patents
Leaver-Fay's latest patents include groundbreaking inventions such as "IgG bispecific antibodies and processes for preparation." This invention provides fully IgG bi-specific antibodies that comprise designed residues in the interface of the heavy chain-heavy chain (C3/C3) domains. It also details processes for preparing these antibodies, along with nucleic acids, vectors, and host cells encoding the same. Another significant patent is "Methods for producing fabs and IgG bispecific antibodies." This patent outlines methods for producing Fabs and IgG bi-specific antibodies by expressing nucleic acids that encode designed residues in the CH1/CL interface. The patent also includes Fabs and IgG bi-specific antibodies produced through these methods, as well as the necessary nucleic acids, vectors, and host cells.
Career Highlights
Throughout his career, Leaver-Fay has worked with prominent organizations such as Eli Lilly and Company and the University of North Carolina at Chapel Hill. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
Leaver-Fay has collaborated with notable colleagues, including Stephen John Demarest and Karen Jean Froning. These partnerships have further enriched his work and expanded the impact of his inventions.
Conclusion
Andrew Philip Leaver-Fay is a distinguished inventor whose work in bi-specific antibodies has the potential to transform therapeutic approaches. His innovative patents and collaborations highlight his commitment to advancing science and technology in this vital field.